Skip to main content
. 2022 Dec 23;46(1):36–41. doi: 10.1016/j.htct.2022.11.008

Table 2.

Percentage of patients by profile benefited by EHL rFVIII.

Profile Proportion of benefited patients by EHL rFVIII (%)
Bleeding profile 30 - 40
Unfavourable PK 30 - 40
Low adherence 10 - 15
High daily activity 10 - 15

PK: pharmacokinetics; EHL: Extended half-life; rFVIII: recombinant factor VIII.